Novelix Pharmaceuticals Ltd

NOVELIX Share Price

BSE

₹57.904.25% (-2.57)

Health Care

Pharmaceuticals

Smallcap

With a market cap of ₹114 cr, stock is ranked 3,001

High Risk

Stock is 4.37x as volatile as Nifty

NOVELIX Stock Scorecard

Performance

High

The creamy layer - amongst the top performing stocks

Valuation

High

Seems to be overvalued vs the market average

Growth

Avg

Financials growth has been moderate for a few years

Profitability

Avg

Average profitability - not good, not bad

Entry point

Avg

The stock is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health Care

Pharmaceuticals

Smallcap

With a market cap of ₹114 cr, stock is ranked 3,001

High Risk

Stock is 4.37x as volatile as Nifty

NOVELIX Performance & Key Metrics

No LabelNo Label	PB RatioPB Ratio	Dividend YieldDiv. Yield
63.02	6.50	—

Sector PESector PE	Sector PBSector PB	Sector Div YldSctr Div Yld
36.71	5.79	0.58%

NOVELIX Analyst Ratings & Forecast

—

Analyst Ratings data is currently unavailable for this stock

Price Upside

Earnings Growth

Rev. Growth

NOVELIX Company Profile

Novelix Pharmaceuticals Ltd engages in trading pharmaceuticals and related products, alongside investments in shares and securities.

NOVELIX Similar Stocks (Peers)

Compare with peers Compare with peers

NOVELIX Similar Stocks (Peers)

Compare with peers Compare with peers

Sun Pharmaceutical Industries Ltd

SUNPHARMA

PE Ratio

38.47

1Y Return

10.56%

Buy Reco %

94.29

Torrent Pharmaceuticals Ltd

TORNTPHARM

PE Ratio

77.37

1Y Return

47.65%

Buy Reco %

81.48

Cipla Ltd

CIPLA

PE Ratio

20.71

1Y Return

3.97%

Buy Reco %

54.84

Dr Reddy's Laboratories Ltd

DRREDDY

PE Ratio

19.06

1Y Return

15.61%

Buy Reco %

48.39

Lupin Ltd

LUPIN

PE Ratio

32.19

1Y Return

18.34%

Buy Reco %

72.22

Compare with Peers

NOVELIX Forecast

NOVELIX Forecasts

NOVELIX

Income

Balance Sheet

Cash Flow

Financial Year		FY 2017		FY 2018		FY 2019		FY 2020		FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	TTM
Total Revenue	3.65	3.12	3.72	1.50	1.31	1.39	1.92	4.53	30.74	128.00
Raw Materials	3.07	1.99	2.77	0.73	0.88	1.09	1.64	4.21	29.22	125.55
Power & Fuel Cost	0.00	0.00	0.00	0.02	0.01	0.01	0.01	0.01	0.00
Employee Cost	0.00	0.13	0.18	0.13	0.15	0.14	0.16	0.13	0.07
Selling & Administrative Expenses	0.48	0.33	0.42	0.35	0.31	0.38	0.36	0.35	0.91
Operating & Other expenses	-0.22	0.24	0.04	0.08	3.15	1.27	-0.25	-0.23	0.37
EBITDA	0.32	0.43	0.31	0.19	-3.19	-1.50	-0.00	0.06	0.17	2.45
Depreciation/Amortization	0.12	0.15	0.12	0.08	0.08	0.07	0.06	0.04	0.04	0.07
PBIT	0.20	0.28	0.19	0.11	-3.27	-1.57	-0.06	0.02	0.13	2.38
Interest & Other Items	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
PBT	0.20	0.28	0.19	0.11	-3.27	-1.57	-0.06	0.02	0.13	2.38
Taxes & Other Items	0.05	0.10	-0.06	0.02	0.00	-0.01	0.00	0.01	0.04	0.57
Net Income	0.15	0.18	0.25	0.09	-3.27	-1.56	-0.06	0.01	0.09	1.81
EPS	0.19	0.22	0.31	0.11	-4.04	-1.93	-0.07	0.01	0.10	1.82
DPS	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout ratio	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00

NOVELIX Income Statement

Quarter		sep 2023		dec 2023		mar 2024		jun 2024		sep 2024	dec 2024	mar 2025	jun 2025	sep 2025	dec 2025
Total Revenue	0.98	0.58	0.97	0.70	3.87	5.30	20.86	22.35	36.39	48.40
Operating & Other expenses	1.03	0.61	0.69	1.04	3.74	5.17	20.63	22.17	35.66	47.09
EBITDA	-0.05	-0.03	0.28	-0.34	0.13	0.13	0.23	0.18	0.73	1.31
Depreciation/Amortization	0.01	0.01	0.01	0.00	0.00	0.00	0.02	0.01	0.01	0.03
PBIT	-0.06	-0.04	0.27	-0.34	0.13	0.13	0.21	0.17	0.72	1.28
Interest & Other Items	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
PBT	-0.06	-0.04	0.27	-0.34	0.13	0.13	0.21	0.17	0.72	1.28
Taxes & Other Items	0.00	0.00	0.00	0.01	0.00	-0.02	0.03	0.07	0.19	0.28
Net Income	-0.06	-0.04	0.27	-0.35	0.13	0.15	0.18	0.10	0.53	1.00
EPS	-0.08	-0.04	0.34	-0.43	0.16	0.15	0.18	0.09	0.37	0.58

Financial Year		FY 2016		FY 2017		FY 2018		FY 2019		FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025
Cash from Operating Activities	2.03	-1.07	1.08	-0.44	1.21	0.58	0.59	-2.41	-0.34	-13.68
Cash from Investing Activities	-1.76	0.97	-1.27	0.45	-0.42	0.21	0.28	0.08	0.19	2.93
Cash from Financing Activities	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	11.32
Net Change in Cash	+0.27	-0.10	-0.19	+0.01	+0.79	+0.79	+0.87	-2.33	-0.15	+0.57
Changes in Working Capital	+1.72	-1.47	+0.66	-0.52	+1.50	+4.09	+1.12	-1.89	-0.09	-13.83
Capital Expenditures	0.14	0.16	0.23	0.06	0.01	0.30	1.86	0.00	0.00	0.11
Free Cash Flow	1.89	-1.23	0.85	-0.50	1.20	0.28	-1.27	-2.41	-0.34	-13.79

NOVELIX Company Updates

FY 2025FY 2025

Annual report

PDF

FY 2024FY 2024

Annual report

PDF

FY 2023FY 2023

Annual report

PDF

FY 2022FY 2022

Annual report

PDF

FY 2021FY 2021

Annual report

PDF

FY 2020FY 2020

Annual report

PDF

FY 2019FY 2019

Annual report

PDF

FY 2018FY 2018

Annual report

PDF

FY 2017FY 2017

Annual report

PDF

NOVELIX Stock Peers

NOVELIX Past Performance & Peer Comparison

Comparing 3 stocks from
Health CarePharmaceuticals

Valuation

Technical

Forecast

Compare valuation on Screener

Stock	PE RatioPE Ratio	PB RatioPB Ratio	Div. YieldDividend Yield
Novelix Pharmaceuticals Ltd	1,267.42	6.50	—
Sun Pharmaceutical Industries Ltd	38.47	5.80	0.91%
Torrent Pharmaceuticals Ltd	77.37	19.48	0.73%
Cipla Ltd	20.71	3.49	1.18%

NOVELIX Stock Price Comparison

Compare NOVELIX with any stock or ETF

NOVELIX

NOVELIX Holdings

NOVELIX Shareholdings

NOVELIX Promoter Holdings Trend

NOVELIX Institutional Holdings Trend

NOVELIX Shareholding Pattern

NOVELIX Shareholding History

Foreign Institutions

NOVELIX Insider Trades & Bulk Stock Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases containing NOVELIX stock

Looks like this stock is not in any smallcase yet.

NOVELIX Events

NOVELIX Dividend Trend

Dividends

Corp. Actions

Announcements

Legal Orders

NOVELIX Dividend Trend

NOVELIX Upcoming Dividends

No upcoming dividends are available

NOVELIX Past Dividends

Cash Dividend

Ex DateEx DateAug 16, 2012

Final

Final | Div/Share: ₹0.30

Dividend/Share

₹0.30

Ex DateEx Date

Aug 16, 2012

Cash Dividend

Ex DateEx DateSep 22, 2011

Final

Final | Div/Share: ₹0.30

Dividend/Share

₹0.30

Ex DateEx Date

Sep 22, 2011

NOVELIX Corp. Actions

Hmm, looks like data is unavailable here. Please come back after some time

No upcoming announcements are available

Insider Trading / SAST

Announced OnFeb 18, 2026

Novelix Pharmaceuticals Ltd - 536565 - D

Novelix Pharmaceuticals Ltd - 536565 - D Download

Link

Download

Announced On

Feb 18, 2026

Insider Trading / SAST

Announced OnFeb 18, 2026

Novelix Pharmaceuticals Ltd - 536565 - D

Novelix Pharmaceuticals Ltd - 536565 - D Download

Link

Download

Announced On

Feb 18, 2026

Insider Trading / SAST

Announced OnFeb 18, 2026

Novelix Pharmaceuticals Ltd - 536565 - D

Novelix Pharmaceuticals Ltd - 536565 - D Download

Link

Download

Announced On

Feb 18, 2026

Insider Trading / SAST

Announced OnFeb 17, 2026

Novelix Pharmaceuticals Ltd - 536565 - D

Novelix Pharmaceuticals Ltd - 536565 - D Download

Link

Download

Announced On

Feb 17, 2026

Company Update

Announced OnFeb 14, 2026

Novelix Pharmaceuticals Ltd - 536565 - A

Novelix Pharmaceuticals Ltd - 536565 - A Download

Link

Download

Announced On

Feb 14, 2026

NOVELIX Legal Orders

Hmm, looks like data is unavailable here. Please come back after some time

NOVELIX Stock News & Opinions

Earnings

Novelix Pharmaceuticals standalone net profit rises 566.67% in the December 2025 quarter

Net profit of Novelix Pharmaceuticals rose 566.67% to Rs 1.00 crore in the quarter ended December 2025 as against Rs 0.15 crore during the previous quarter ended December 2024. Sales rose 813.21% to Rs 48.40 crore in the quarter ended December 2025 as against Rs 5.30 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales48.405.30 813 OPM %2.712.45 - PBDT1.310.13 908 PBT1.280.13 885 NP1.000.15 567 Powered by Capital Market - Live

1 week agoCapital Market - Live

Corporate

Novelix Pharmaceuticals board approves allotment of 23.20 lakh equity shares

The board of Novelix Pharmaceuticals at its meeting held on 12 February 2026 has approved allotment of 23,20,000 equity shares of Rs 10 each at an issue price of Rs 60 per equity share (including a premium of Rs 50 per equity share) by way of preferential issue through private placement. Powered by Capital Market - Live

2 weeks agoCapital Market - Live

Corporate

Novelix Pharmaceuticals to conduct board meeting

Novelix Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 12 February 2026.Powered by Capital Market - Live

3 weeks agoCapital Market - Live

Corporate

Novelix Pharmaceuticals EGM scheduled

Novelix Pharmaceuticals announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 9 January 2026.Powered by Capital Market - Live

2 months agoCapital Market - Live

Corporate

Novelix Pharmaceuticals EGM scheduled

Novelix Pharmaceuticals announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 9 January 2026.Powered by Capital Market - Live

2 months agoCapital Market - Live

Corporate

Novelix Pharmaceuticals to convene board meeting

Novelix Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 11 December 2025.Powered by Capital Market - Live

2 months agoCapital Market - Live

Earnings

Novelix Pharmaceuticals standalone net profit rises 307.69% in the September 2025 quarter

Net profit of Novelix Pharmaceuticals rose 307.69% to Rs 0.53 crore in the quarter ended September 2025 as against Rs 0.13 crore during the previous quarter ended September 2024. Sales rose 818.18% to Rs 36.36 crore in the quarter ended September 2025 as against Rs 3.96 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales36.363.96 818 OPM %1.935.30 - PBDT0.730.13 462 PBT0.720.13 454 NP0.530.13 308 Powered by Capital Market - Live

3 months agoCapital Market - Live

Corporate

Novelix Pharmaceuticals to convene board meeting

Novelix Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 13 November 2025.Powered by Capital Market - Live

3 months agoCapital Market - Live

Corporate

Novelix Pharmaceuticals to conduct AGM

Novelix Pharmaceuticals announced that the 31th Annual General Meeting(AGM) of the company will be held on 19 September 2025.Powered by Capital Market - Live

6 months agoCapital Market - Live

Earnings

Novelix Pharmaceuticals reports standalone net profit of Rs 0.11 crore in the June 2025 quarter

Net profit of Novelix Pharmaceuticals reported to Rs 0.11 crore in the quarter ended June 2025 as against net loss of Rs 0.35 crore during the previous quarter ended June 2024. Sales rose 3625.00% to Rs 22.35 crore in the quarter ended June 2025 as against Rs 0.60 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales22.350.60 3625 OPM %0.85-73.33 - PBDT0.19-0.34 LP PBT0.18-0.34 LP NP0.11-0.35 LP Powered by Capital Market - Live

6 months agoCapital Market - Live

Frequently asked questions

What is the share price of Novelix Pharmaceuticals Ltd (NOVELIX) today?
The share price of NOVELIX as on 2nd March 2026 is ₹57.90. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.
What is the return on Novelix Pharmaceuticals Ltd (NOVELIX) share?
The past returns of Novelix Pharmaceuticals Ltd (NOVELIX) share are
- Past 1 week: -6.61%
- Past 1 month: -4.00%
- Past 3 months: -13.51%
- Past 6 months: 35.08%
- Past 1 year: 125.72%
- Past 3 years: 573.18%
- Past 5 years: 1236.92%
What are the peers or stocks similar to Novelix Pharmaceuticals Ltd (NOVELIX)?
The peers or stocks similar to Novelix Pharmaceuticals Ltd (NOVELIX) include:
What is the market cap of Novelix Pharmaceuticals Ltd (NOVELIX) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Novelix Pharmaceuticals Ltd (NOVELIX) is ₹114.07 Cr as of 2nd March 2026.
What is the 52 week high and low of Novelix Pharmaceuticals Ltd (NOVELIX) share?
The 52-week high of Novelix Pharmaceuticals Ltd (NOVELIX) is ₹70.16 and the 52-week low is ₹25.35.
What is the PE and PB ratio of Novelix Pharmaceuticals Ltd (NOVELIX) stock?
The P/E (price-to-earnings) ratio of Novelix Pharmaceuticals Ltd (NOVELIX) is 1267.42. The P/B (price-to-book) ratio is 6.50.
Which sector does Novelix Pharmaceuticals Ltd (NOVELIX) belong to?
Novelix Pharmaceuticals Ltd (NOVELIX) belongs to the Health Care sector & Pharmaceuticals sub-sector.
How to buy Novelix Pharmaceuticals Ltd (NOVELIX) shares?
You can directly buy Novelix Pharmaceuticals Ltd (NOVELIX) shares on Tickertape. Simply sign up, connect your demat account and place your order.

Stock	VolatilityVolatility	RSI–14DRSI – 14D	Price Mom RankPrice Momentum Rank
Novelix Pharmaceuticals Ltd	52.01%	35.98	Pro
Sun Pharmaceutical Industries Ltd	20.13%	61.18
Torrent Pharmaceuticals Ltd	20.99%	73.82
Cipla Ltd	20.38%	52.88

Novelix Pharmaceuticals Ltd

NOVELIX Share Price

NOVELIX Stock Scorecard

NOVELIX Performance & Key Metrics

NOVELIX Performance & Key Metrics

NOVELIX Analyst Ratings & Forecast

Price Upside

Earnings Growth

Rev. Growth

NOVELIX Company Profile

NOVELIX Similar Stocks (Peers)

NOVELIX Similar Stocks (Peers)

NOVELIX Forecast

NOVELIX Forecasts

NOVELIX